Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in Oncogene Retrieve available abstracts of 49 articles: HTML format

Single Articles

June 2024
1. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
   TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
   Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
   PubMed     Abstract available
   
   
   May 2024
2. PATTERSON MR, Meijers AS, Ryder EL, Wootton LM, et al
   E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.
   Oncogene. 2024 May 24. doi: 10.1038/s41388-024-03067.
   PubMed     Abstract available
   
   
   
3. ZHANG C, Xu Y, Zhu X, Zhang X, et al
   Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
   Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
   PubMed     Abstract available
   
   
   April 2024
4. SHAN W, Peng W, Chen Y, Wang Y, et al
   GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
   Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
   PubMed     Abstract available
   
   
   
5. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
   Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
   Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
   PubMed     Abstract available
   
   
   
6. WEI Y, Chen Z, Li Y, Song K, et al
   The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
   Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
   PubMed     Abstract available
   
   
   February 2024
7. MERIL S, Muhlbauer Avni M, Lior C, Bahlsen M, et al
   Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients.
   Oncogene. 2024 Feb 22. doi: 10.1038/s41388-024-02981.
   PubMed     Abstract available
   
   
   January 2024
8. WU J, Wu Y, Chen S, Guo Q, et al
   PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
   Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
   PubMed     Abstract available
   
   
   
9. LIU H, Deng S, Yao X, Liu Y, et al
   Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
   Oncogene. 2024 Jan 15. doi: 10.1038/s41388-024-02940.
   PubMed     Abstract available
   
   
   
10. WU CJ, Pan KF, Chen JQ, Tao Y-, et al
    Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
    Oncogene. 2024 Jan 4. doi: 10.1038/s41388-023-02918.
    PubMed     Abstract available
    
    
    December 2023
11. YU X, Zhao P, Luo Q, Wu X, et al
    RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-kappaB activation and ovarian cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02910.
    PubMed     Abstract available
    
    
    November 2023
12. AKINJIYAN FA, Ibitoye Z, Zhao P, Shriver LP, et al
    DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02884.
    PubMed     Abstract available
    
    
    
13. CALLENS C, Rodrigues M, Briaux A, Frouin E, et al
    Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Oncogene. 2023;42:3556-3563.
    PubMed     Abstract available
    
    
    October 2023
14. TAO YP, Zhu HY, Shi QY, Wang CX, et al
    S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway.
    Oncogene. 2023 Oct 12. doi: 10.1038/s41388-023-02853.
    PubMed     Abstract available
    
    
    September 2023
15. PETTITT SJ, Shao N, Zatreanu D, Frankum J, et al
    A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-?11q splice variant.
    Oncogene. 2023;42:2701-2709.
    PubMed     Abstract available
    
    
    August 2023
16. EL BABA R, Haidar Ahmad S, Monnien F, Mansar R, et al
    Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells.
    Oncogene. 2023 Aug 26. doi: 10.1038/s41388-023-02813.
    PubMed     Abstract available
    
    
    
17. RAY U, Thirusangu P, Jin L, Xiao Y, et al
    PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
    Oncogene. 2023 Aug 7. doi: 10.1038/s41388-023-02785.
    PubMed     Abstract available
    
    
    July 2023
18. SCARTH JA, Wasson CW, Patterson MR, Evans D, et al
    Exploitation of ATP-sensitive potassium ion (K(ATP)) channels by HPV promotes cervical cancer cell proliferation by contributing to MAPK/AP-1 signalling.
    Oncogene. 2023 Jul 13. doi: 10.1038/s41388-023-02772.
    PubMed     Abstract available
    
    
    
19. HEINZL N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, et al
    Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
    Oncogene. 2023 Jul 4. doi: 10.1038/s41388-023-02758.
    PubMed     Abstract available
    
    
    June 2023
20. LI Y, Chen Z, Peng J, Yuan C, et al
    The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
    Oncogene. 2023 Jun 30. doi: 10.1038/s41388-023-02763.
    PubMed     Abstract available
    
    
    April 2023
21. JIANG Y, Song L, Lin Y, Nowialis P, et al
    ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02679.
    PubMed     Abstract available
    
    
    March 2023
22. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02629.
    PubMed    
    
    
    
23. CHEN K, Yuan X, Wang S, Zheng F, et al
    MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650.
    PubMed     Abstract available
    
    
    January 2023
24. ZHANG C, Jiang H, Yuan L, Liao Y, et al
    CircVPRBP inhibits nodal metastasis of cervical cancer by impeding RACK1 O-GlcNAcylation and stability.
    Oncogene. 2023 Jan 19. doi: 10.1038/s41388-023-02595.
    PubMed     Abstract available
    
    
    December 2022
25. LI G, Yi X, Du S, Gong L, et al
    Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition.
    Oncogene. 2022 Dec 8. doi: 10.1038/s41388-022-02560.
    PubMed     Abstract available
    
    
    November 2022
26. WANG M, Yan Q, Song Y, Zhang Z, et al
    Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
    Oncogene. 2022 Nov 29. doi: 10.1038/s41388-022-02550.
    PubMed     Abstract available
    
    
    
27. HE Y, OuYang Z, Liu W, Chen Y, et al
    TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing.
    Oncogene. 2022 Nov 11. pii: 10.1038/s41388-022-02539.
    PubMed     Abstract available
    
    
    October 2022
28. HUANG TT, Burkett SS, Tandon M, Yamamoto TM, et al
    Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
    Oncogene. 2022 Oct 12. pii: 10.1038/s41388-022-02491.
    PubMed     Abstract available
    
    
    August 2022
29. DU QY, Huo FC, Du WQ, Sun XL, et al
    METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA.
    Oncogene. 2022 Aug 20. pii: 10.1038/s41388-022-02435.
    PubMed     Abstract available
    
    
    July 2022
30. SHEN Z, Gu L, Liu Y, Wang L, et al
    PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA.
    Oncogene. 2022 Jul 22. pii: 10.1038/s41388-022-02411.
    PubMed     Abstract available
    
    
    June 2022
31. HUANG C, Lv X, Chen P, Liu J, et al
    Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02390.
    PubMed     Abstract available
    
    
    
32. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    Correction to: An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2022 Jun 6. pii: 10.1038/s41388-022-02356.
    PubMed    
    
    
    May 2022
33. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 May 30. pii: 10.1038/s41388-022-02354.
    PubMed    
    
    
    April 2022
34. ZHU S, Zhang C, Cao D, Bai J, et al
    Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
    Oncogene. 2022 Apr 25. pii: 10.1038/s41388-022-02277.
    PubMed     Abstract available
    
    
    
35. KOMATSU M, Nakamura K, Takeda T, Chiwaki F, et al
    Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling.
    Oncogene. 2022;41:2326-2339.
    PubMed     Abstract available
    
    
    March 2022
36. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 Mar 18. pii: 10.1038/s41388-022-02251.
    PubMed     Abstract available
    
    
    February 2022
37. YOSHIDA A, Phillips-Mason P, Tarallo V, Avril S, et al
    Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss.
    Oncogene. 2022 Feb 24. pii: 10.1038/s41388-022-02243.
    PubMed     Abstract available
    
    
    
38. KWON J, Choi H, Ware AD, Morillo BC, et al
    USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model.
    Oncogene. 2022 Feb 16. pii: 10.1038/s41388-022-02224.
    PubMed     Abstract available
    
    
    
39. LIAO Y, Huang J, Liu P, Zhang C, et al
    Downregulation of LNMAS orchestrates partial EMT and immune escape from macrophage phagocytosis to promote lymph node metastasis of cervical cancer.
    Oncogene. 2022 Feb 12. pii: 10.1038/s41388-022-02202.
    PubMed     Abstract available
    
    
    
40. MOTA A, Oltra SS, Selenica P, Moiola CP, et al
    Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
    Oncogene. 2022 Feb 10. pii: 10.1038/s41388-022-02221.
    PubMed     Abstract available
    
    
    
41. LIN L, Shi K, Zhou S, Cai MC, et al
    SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
    Oncogene. 2022 Feb 5. pii: 10.1038/s41388-022-02210.
    PubMed     Abstract available
    
    
    January 2022
42. LI J, Zheng C, Wang M, Umano AD, et al
    ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer.
    Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02149.
    PubMed     Abstract available
    
    
    
43. JAMES NE, Woodman M, Ribeiro JR
    Prognostic immunologic signatures in epithelial ovarian cancer.
    Oncogene. 2022 Jan 14. pii: 10.1038/s41388-022-02181.
    PubMed     Abstract available
    
    
    
44. KAN T, Zhang S, Zhou S, Zhang Y, et al
    Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.
    Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02139.
    PubMed     Abstract available
    
    
    November 2021
45. YIN L, Zeng Y, Zeng R, Chen Y, et al
    Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02117.
    PubMed     Abstract available
    
    
    
46. BOUDHRAA Z, Zaoui K, Fleury H, Cahuzac M, et al
    NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02082.
    PubMed     Abstract available
    
    
    May 2021
47. KUMAGAI K, Takanashi M, Ohno SI, Harada Y, et al
    WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7.
    Oncogene. 2021;40:3695-3706.
    PubMed     Abstract available
    
    
    April 2021
48. ALI R, Alblihy A, Miligy IM, Alabdullah ML, et al
    Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    Oncogene. 2021;40:2496-2508.
    PubMed     Abstract available
    
    
    March 2021
49. NI M, Li J, Zhao H, Xu F, et al
    BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
    Oncogene. 2021 Mar 12. pii: 10.1038/s41388-021-01735.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.